Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York. more
Time Frame | CGTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 21.04% | 2.44% | 2.58% |
1-Month Return | 89.72% | -4.49% | 0.09% |
3-Month Return | 87.17% | -8.82% | 4.76% |
6-Month Return | -54.86% | -4.46% | 9.89% |
1-Year Return | -56.4% | 3.16% | 26.47% |
3-Year Return | -87.72% | -0.83% | 25.98% |
5-Year Return | -93.99% | 35.65% | 86.34% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 81.00K | 98.00K | 93.00K | 235.00K | 252.00K | [{"date":"2019-12-31","value":32.14,"profit":true},{"date":"2020-12-31","value":38.89,"profit":true},{"date":"2021-12-31","value":36.9,"profit":true},{"date":"2022-12-31","value":93.25,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (81.00K) | (98.00K) | (93.00K) | (235.00K) | (252.00K) | [{"date":"2019-12-31","value":-8100000,"profit":false},{"date":"2020-12-31","value":-9800000,"profit":false},{"date":"2021-12-31","value":-9300000,"profit":false},{"date":"2022-12-31","value":-23500000,"profit":false},{"date":"2023-12-31","value":-25200000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 4.67M | 6.55M | 11.15M | 21.33M | 50.72M | [{"date":"2019-12-31","value":9.2,"profit":true},{"date":"2020-12-31","value":12.92,"profit":true},{"date":"2021-12-31","value":21.98,"profit":true},{"date":"2022-12-31","value":42.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (17.83M) | (17.41M) | (28.60M) | (43.55M) | (50.72M) | [{"date":"2019-12-31","value":-1783100000,"profit":false},{"date":"2020-12-31","value":-1740700000,"profit":false},{"date":"2021-12-31","value":-2859800000,"profit":false},{"date":"2022-12-31","value":-4355100000,"profit":false},{"date":"2023-12-31","value":-5072400000,"profit":false}] |
Total Non-Operating Income/Expense | 11.96M | 7.82M | 15.99M | 22.13M | 24.91M | [{"date":"2019-12-31","value":48.04,"profit":true},{"date":"2020-12-31","value":31.38,"profit":true},{"date":"2021-12-31","value":64.19,"profit":true},{"date":"2022-12-31","value":88.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (4.84M) | (7.84M) | (11.72M) | (21.40M) | (25.79M) | [{"date":"2019-12-31","value":-484200000,"profit":false},{"date":"2020-12-31","value":-783900000,"profit":false},{"date":"2021-12-31","value":-1171600000,"profit":false},{"date":"2022-12-31","value":-2139700000,"profit":false},{"date":"2023-12-31","value":-2578800000,"profit":false}] |
Income Taxes | 2.11M | 2.23M | (1.43M) | (22.15M) | - | [{"date":"2019-12-31","value":94.54,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-64.08,"profit":false},{"date":"2022-12-31","value":-992.12,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (6.95M) | (10.07M) | (10.29M) | 757.00K | - | [{"date":"2019-12-31","value":-918.49,"profit":false},{"date":"2020-12-31","value":-1330.52,"profit":false},{"date":"2021-12-31","value":-1358.65,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (4.84M) | (7.84M) | (11.72M) | (43.61M) | (22.83M) | [{"date":"2019-12-31","value":-484200000,"profit":false},{"date":"2020-12-31","value":-783900000,"profit":false},{"date":"2021-12-31","value":-1171600000,"profit":false},{"date":"2022-12-31","value":-4361400000,"profit":false},{"date":"2023-12-31","value":-2282900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (6.95M) | (10.07M) | (10.29M) | 757.00K | (25.79M) | [{"date":"2019-12-31","value":-918.49,"profit":false},{"date":"2020-12-31","value":-1330.52,"profit":false},{"date":"2021-12-31","value":-1358.65,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-3406.61,"profit":false}] |
EPS (Diluted) | (7.58) | (7.24) | (24.80) | (0.91) | (0.86) | [{"date":"2019-12-31","value":-757.62,"profit":false},{"date":"2020-12-31","value":-723.59,"profit":false},{"date":"2021-12-31","value":-2479.54,"profit":false},{"date":"2022-12-31","value":-91,"profit":false},{"date":"2023-12-31","value":-86,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CGTX | |
---|---|
Cash Ratio | 1.73 |
Current Ratio | 2.11 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CGTX | |
---|---|
ROA (LTM) | -93.70% |
ROE (LTM) | -108.31% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CGTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.47 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.53 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CGTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.76 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Cognition Therapeutics Inc (CGTX) share price today is $0.7674
Yes, Indians can buy shares of Cognition Therapeutics Inc (CGTX) on Vested. To buy Cognition Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CGTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cognition Therapeutics Inc (CGTX) via the Vested app. You can start investing in Cognition Therapeutics Inc (CGTX) with a minimum investment of $1.
You can invest in shares of Cognition Therapeutics Inc (CGTX) via Vested in three simple steps:
The 52-week high price of Cognition Therapeutics Inc (CGTX) is $2.95. The 52-week low price of Cognition Therapeutics Inc (CGTX) is $0.34.
The price-to-earnings (P/E) ratio of Cognition Therapeutics Inc (CGTX) is
The price-to-book (P/B) ratio of Cognition Therapeutics Inc (CGTX) is 1.76
The dividend yield of Cognition Therapeutics Inc (CGTX) is 0.00%
The market capitalization of Cognition Therapeutics Inc (CGTX) is $25.51M
The stock symbol (or ticker) of Cognition Therapeutics Inc is CGTX